Sakar Healthcare Limited (SAKAR) - Net Assets
Based on the latest financial reports, Sakar Healthcare Limited (SAKAR) has net assets worth Rs3.03 Billion INR (≈ $32.80 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs4.49 Billion ≈ $48.51 Million USD) and total liabilities (Rs1.45 Billion ≈ $15.72 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Sakar Healthcare Limited to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs3.03 Billion |
| % of Total Assets | 67.6% |
| Annual Growth Rate | 23.29% |
| 5-Year Change | 189.96% |
| 10-Year Change | 1388.22% |
| Growth Volatility | 23.16 |
Sakar Healthcare Limited - Net Assets Trend (2010–2025)
This chart illustrates how Sakar Healthcare Limited's net assets have evolved over time, based on quarterly financial data. Also explore Sakar Healthcare Limited assets under control for the complete picture of this company's asset base.
Annual Net Assets for Sakar Healthcare Limited (2010–2025)
The table below shows the annual net assets of Sakar Healthcare Limited from 2010 to 2025. For live valuation and market cap data, see how much is Sakar Healthcare Limited worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs2.85 Billion ≈ $30.87 Million |
+8.82% |
| 2024-03-31 | Rs2.62 Billion ≈ $28.37 Million |
+51.33% |
| 2023-03-31 | Rs1.73 Billion ≈ $18.75 Million |
+36.00% |
| 2022-03-31 | Rs1.27 Billion ≈ $13.78 Million |
+29.47% |
| 2021-03-31 | Rs984.52 Million ≈ $10.65 Million |
+21.07% |
| 2020-03-31 | Rs813.20 Million ≈ $8.79 Million |
+13.41% |
| 2019-03-31 | Rs717.04 Million ≈ $7.75 Million |
+39.25% |
| 2018-03-31 | Rs514.93 Million ≈ $5.57 Million |
+45.04% |
| 2017-03-31 | Rs355.03 Million ≈ $3.84 Million |
+85.08% |
| 2016-03-31 | Rs191.82 Million ≈ $2.07 Million |
+29.37% |
| 2015-03-31 | Rs148.28 Million ≈ $1.60 Million |
+6.90% |
| 2014-03-31 | Rs138.71 Million ≈ $1.50 Million |
+14.46% |
| 2013-03-31 | Rs121.19 Million ≈ $1.31 Million |
-11.92% |
| 2012-03-31 | Rs137.59 Million ≈ $1.49 Million |
+3.65% |
| 2011-03-31 | Rs132.75 Million ≈ $1.44 Million |
+7.47% |
| 2010-03-31 | Rs123.53 Million ≈ $1.34 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Sakar Healthcare Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5135.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs980.38 Million | 34.34% |
| Common Stock | Rs219.50 Million | 7.69% |
| Other Comprehensive Income | Rs28.80 Million | 1.01% |
| Other Components | Rs1.63 Billion | 56.96% |
| Total Equity | Rs2.85 Billion | 100.00% |
Sakar Healthcare Limited Competitors by Market Cap
The table below lists competitors of Sakar Healthcare Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Om Holdings Ltd
AU:OMH
|
$149.10 Million |
|
Fiamma Holdings Bhd
KLSE:6939
|
$149.12 Million |
|
PPX Mining Corp
V:PPX
|
$149.12 Million |
|
Orion Office Reit Inc
NYSE:ONL
|
$149.23 Million |
|
NanoenTekInc
KQ:039860
|
$149.06 Million |
|
KJTS
KLSE:0293
|
$149.05 Million |
|
United Paper Public Company Limited
BK:UTP
|
$148.91 Million |
|
HomesToLife Ltd
NASDAQ:HTLM
|
$148.88 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sakar Healthcare Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,623,311,000 to 2,854,759,000, a change of 231,448,000 (8.8%).
- Net income of 175,020,000 contributed positively to equity growth.
- Share repurchases of 57,600,000 reduced equity.
- New share issuances of 57,600,000 increased equity.
- Other comprehensive income decreased equity by 12,114,000.
- Other factors increased equity by 68,542,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs175.02 Million | +6.13% |
| Share Repurchases | Rs57.60 Million | -2.02% |
| Share Issuances | Rs57.60 Million | +2.02% |
| Other Comprehensive Income | Rs-12.11 Million | -0.42% |
| Other Changes | Rs68.54 Million | +2.4% |
| Total Change | Rs- | 8.82% |
Book Value vs Market Value Analysis
This analysis compares Sakar Healthcare Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.79x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 37.62x to 4.79x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-03-31 | Rs16.69 | Rs628.05 | x |
| 2011-03-31 | Rs17.93 | Rs628.05 | x |
| 2012-03-31 | Rs17.20 | Rs628.05 | x |
| 2013-03-31 | Rs15.15 | Rs628.05 | x |
| 2014-03-31 | Rs17.34 | Rs628.05 | x |
| 2015-03-31 | Rs18.53 | Rs628.05 | x |
| 2016-03-31 | Rs23.98 | Rs628.05 | x |
| 2017-03-31 | Rs32.39 | Rs628.05 | x |
| 2018-03-31 | Rs34.42 | Rs628.05 | x |
| 2019-03-31 | Rs52.78 | Rs628.05 | x |
| 2020-03-31 | Rs54.35 | Rs628.05 | x |
| 2021-03-31 | Rs61.55 | Rs628.05 | x |
| 2022-03-31 | Rs84.41 | Rs628.05 | x |
| 2023-03-31 | Rs93.23 | Rs628.05 | x |
| 2024-03-31 | Rs127.81 | Rs628.05 | x |
| 2025-03-31 | Rs131.00 | Rs628.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sakar Healthcare Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.13%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.86%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.45x
- Recent ROE (6.13%) is below the historical average (9.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 6.61% | 5.10% | 0.36x | 3.62x | Rs-4.19 Million |
| 2011 | 5.18% | 3.42% | 0.41x | 3.68x | Rs-6.39 Million |
| 2012 | 5.60% | 4.76% | 0.32x | 3.63x | Rs-6.05 Million |
| 2013 | 11.92% | 6.60% | 0.44x | 4.13x | Rs2.33 Million |
| 2014 | 12.63% | 5.90% | 0.57x | 3.77x | Rs3.65 Million |
| 2015 | 12.39% | 5.24% | 0.70x | 3.38x | Rs3.54 Million |
| 2016 | 11.56% | 5.38% | 0.81x | 2.66x | Rs3.00 Million |
| 2017 | 9.52% | 7.65% | 0.63x | 1.99x | Rs-1.72 Million |
| 2018 | 7.41% | 7.19% | 0.65x | 1.57x | Rs-13.35 Million |
| 2019 | 9.78% | 10.27% | 0.69x | 1.38x | Rs-1.59 Million |
| 2020 | 11.83% | 11.60% | 0.72x | 1.42x | Rs14.91 Million |
| 2021 | 10.85% | 11.28% | 0.53x | 1.81x | Rs8.37 Million |
| 2022 | 11.96% | 11.89% | 0.48x | 2.10x | Rs24.96 Million |
| 2023 | 7.36% | 9.57% | 0.40x | 1.94x | Rs-45.76 Million |
| 2024 | 4.45% | 7.57% | 0.40x | 1.48x | Rs-145.62 Million |
| 2025 | 6.13% | 9.86% | 0.43x | 1.45x | Rs-110.46 Million |
Industry Comparison
This section compares Sakar Healthcare Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $23,713,303,062
- Average return on equity (ROE) among peers: 8.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sakar Healthcare Limited (SAKAR) | Rs3.03 Billion | 6.61% | 0.48x | $149.09 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $988.60 Million | 6.59% | 1.36x | $27.93 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $6.52 Billion | 21.67% | 1.42x | $371.43 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $19.90 Billion | 13.69% | 0.46x | $725.68 Million |
| Abbott India Limited (ABBOTINDIA) | $36.99 Billion | 32.48% | 0.40x | $5.85 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $1.16 Billion | 12.69% | 1.32x | $3.81 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $6.25 Billion | -40.39% | 3.91x | $906.19 Million |
| Alkem Laboratories Limited (ALKEM) | $88.47 Billion | 18.60% | 0.59x | $6.98 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.46 Billion | 16.82% | 0.29x | $178.52 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $51.90 Billion | 11.24% | 0.50x | $1.60 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $23.50 Billion | -5.26% | 1.65x | $8.73 Billion |
About Sakar Healthcare Limited
Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as anti-infective, analge… Read more